The first detected COVID-19 virus in China in late December 2019, has now spread to over 200 countries and territories across the globe. As it is a novel virus, in course of time, new symptoms and new complexities in patients have arisen, which demand immediate attention. This ambiguous, fast mutating nature and strain variations of SARS CoV2 have hindered the way of vaccine development. However, recognizing this new virus as a member of coronavidae family and its similarity with previously prevailed SARS-Cov virus has advantages in order for its further characterization and identification of the route of entry. Hence, this review aims at providing an overview of the viral entry pathway and explaining the reasons behind the vulnerability of an individual based on his/her age, sex, weight, other existing diseases and genetic make-up. It will also try to explicate various newly emerged symptoms of COVID-19 from the perspective of cytokinin storm theory. Furthermore, it summarizes all the therapeutic strategies based on preventing virus entry, some of which are already developed or under trial or yet confined in theory using currently published literature, scientific reports and research articles about SARS-CoV2. This review will help better understand the COVID-19 complicacies with latest concepts on therapeutic strategies against SARS-CoV2.
| Published in | American Journal of Internal Medicine (Volume 9, Issue 2) |
| DOI | 10.11648/j.ajim.20210902.11 |
| Page(s) | 58-69 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
SARS-CoV, COVID-19, ACE2, Viral Entry Pathway, Vaccine Strategy
| [1] | Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, et al: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181: 271-280. e278. |
| [2] | Wang C, Horby PW, Hayden FG, Gao GF: A novel coronavirus outbreak of global health concern. The Lancet 2020, 395: 470-473. |
| [3] | Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G: Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research 2015, 116: 76-84. |
| [4] | Saha S, Chakrabarti S, Singh PK, Poddar J, Satapathi S, Saini S, Kakar SS, Roy P: Physiological Relevance of Angiotensin Converting Enzyme 2 As a Metabolic Linker and Therapeutic Implication of Mesenchymal Stem Cells in COVID-19 and Hypertension. Stem Cell Reviews and Reports 2020. |
| [5] | Rota P, Oberste M, Monroe S, Nix WA, Campagnoli R, Icenogle J, Penaranda S, Bankamp B, Maher K, Chen M, et al: Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300: 1394-1399. |
| [6] | Marra MA, Jones SJM, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YSN, Khattra J, Asano JK, Barber SA, Chan SY, et al: The Genome Sequence of the SARS-Associated Coronavirus. Science 2003, 300: 1399. |
| [7] | Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS: The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 2003, 312: 1159-1164. |
| [8] | Wong SK, Li W, Moore MJ, Choe H, Farzan M: A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 2004, 279: 3197-3201. |
| [9] | Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P: Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020, 63: 457-460. |
| [10] | Li F, Li W, Farzan M, Harrison SC: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005, 309: 1864-1868. |
| [11] | Amirfakhryan H, safari F: Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. Hellenic Journal of Cardiology 2020. |
| [12] | Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al: Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv; 2020. |
| [13] | Tang JW, To KF, Lo AW, Sung JJ, Ng HK, Chan PK: Quantitative temporal-spatial distribution of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in post-mortem tissues. J Med Virol 2007, 79: 1245-1253. |
| [14] | Ferrario CM, Trask AJ, Jessup JA: Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005, 289: H2281-2290. |
| [15] | Tikellis C, Thomas MC: Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int J Pept 2012, 2012: 256294. |
| [16] | Saponaro F, Rutigliano G, Sestito S, Bandini L, Storti B, Bizzarri R, Zucchi R: ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. 2020, 7. |
| [17] | Zisman LS: ACE and ACE2: a tale of two enzymes. European Heart Journal 2005, 26: 322-324. |
| [18] | Bourgonje AR, Abdulle AE, Timens W, Hillebrands J-L, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD, et al: Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). 2020, 251: 228-248. |
| [19] | Tan HW, Xu Y-M, Lau ATY: Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection. Reviews in medical virology 2020, 30: e2122-e2122. |
| [20] | Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, et al: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro surveillance: bulletin Europeen sur les maladies transmissibles=European communicable disease bulletin 2020, 25: 2000045. |
| [21] | Tu H, Tu S, Gao S, Shao A, Sheng J: Current epidemiological and clinical features of COVID-19; a global perspective from China. J Infect 2020, 81: 1-9. |
| [22] | Cui J, Li F, Shi Z-L: Origin and evolution of pathogenic coronaviruses. Nature reviews Microbiology 2019, 17: 181-192. |
| [23] | Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, Gramberg T, Pöhlmann S: Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochemical and biophysical research communications 2004, 319: 1216-1221. |
| [24] | Forni D, Cagliani R, Clerici M, Sironi M: Molecular Evolution of Human Coronavirus Genomes. Trends in microbiology 2017, 25: 35-48. |
| [25] | Rathod SB, Prajapati PB, Punjabi LB, Prajapati KN, Chauhan N, Mansuri MF: Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2. In Silico Pharmacology 2020, 8: 3. |
| [26] | Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F: Cell entry mechanisms of SARS-CoV-2. 2020, 117: 11727-11734. |
| [27] | He W, Liu X, Feng L, Xiong S, Li Y, Chen L, Li Y, Wang G, Li D, Fu B: Impact of SARS-CoV-2 on Male Reproductive Health: A Review of the Literature on Male Reproductive Involvement in COVID-19. 2020, 7. |
| [28] | Jia HP, Look DC, Tan P, Shi L, Hickey M, Gakhar L, Chappell MC, Wohlford-Lenane C, McCray PB, Jr.: Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. American journal of physiology Lung cellular and molecular physiology 2009, 297: L84-L96. |
| [29] | Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW: TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov 2020, 10: 779-782. |
| [30] | de Almeida SMV, Santos Soares JC, dos Santos KL, Alves JEF, Ribeiro AG, Jacob ÍTT, da Silva Ferreira CJ, dos Santos JC, de Oliveira JF, de Carvalho Junior LB, de Lima MdCA: COVID-19 therapy: What weapons do we bring into battle? Bioorganic & Medicinal Chemistry 2020, 28: 115757. |
| [31] | Luo Y, Liu C, Guan T, Li Y, Lai Y, Li F, Zhao H, Maimaiti T, Zeyaweiding A: Association of ACE2 genetic polymorphisms withhypertension-related target organ damages in south Xinjiang. Hypertension Research 2019, 42: 681-689. |
| [32] | Patel VB, Zhong J-C, Grant MB, Oudit GY: Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circulation research 2016, 118: 1313-1326. |
| [33] | Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, Wen F, Huang X, Ning G, Wang W: Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discovery 2020, 6: 11. |
| [34] | Chaudhary M: COVID-19 susceptibility: potential of ACE2 polymorphisms. Egyptian Journal of Medical Human Genetics 2020, 21: 54. |
| [35] | Corley M, Ndhlovu L: DNA Methylation Analysis of the COVID-19 Host Cell Receptor, Angiotensin I Converting Enzyme 2 Gene (ACE2) in the Respiratory System Reveal Age and Gender Differences. 2020. |
| [36] | Miller R, Wentzel AR, Richards GA: COVID-19: NAD (+) deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity. Medical hypotheses 2020, 144: 110044-110044. |
| [37] | Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020, 395: 507-513. |
| [38] | Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, Liu S, Yang J-K: Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. In Frontiers in public health, vol. 8. pp. 152; 2020: 152. |
| [39] | Smith JC, Sheltzer JM: Cigarette smoke triggers the expansion of a subpopulation of respiratory epithelial cells that express the SARS-CoV-2 receptor ACE2. bioRxiv 2020: 2020.2003.2028.013672. |
| [40] | Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L, Nelson PS: Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999, 59: 4180-4184. |
| [41] | Shen LW, Mao HJ, Wu YL, Tanaka Y, Zhang W: TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie 2017, 142: 1-10. |
| [42] | Mjaess G, Karam A, Aoun F, Albisinni S, Roumeguère T: COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. Progrès en Urologie 2020, 30: 484-487. |
| [43] | [43] Pathangey G, Fadadu PP, Hospodar AR, Abbas AE. Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. Am J Physiol Cell Mol Physiol 320: L301–L330, 2021. doi: 10.1152/ajplung.00259.2020. |
| [44] | Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, Stachel A: Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. Clin Infect Dis 2020, 71: 896-897. |
| [45] | Milner JJ, Beck MA: The impact of obesity on the immune response to infection. Proc Nutr Soc 2012, 71: 298-306. |
| [46] | de Heredia FP, Gómez-Martínez S, Marcos A: Obesity, inflammation and the immune system. Proceedings of the Nutrition Society 2012, 71: 332-338. |
| [47] | Jagannathan-Bogdan M, McDonnell ME, Shin H, Rehman Q, Hasturk H, Apovian CM, Nikolajczyk BS: Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol 2011, 186: 1162-1172. |
| [48] | McLaughlin T, Liu LF, Lamendola C, Shen L, Morton J, Rivas H, Winer D, Tolentino L, Choi O, Zhang H, et al: T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler Thromb Vasc Biol 2014, 34: 2637-2643. |
| [49] | Fanelli V, Ranieri VM: Mechanisms and clinical consequences of acute lung injury. Ann Am Thorac Soc 2015, 12 Suppl 1: S3-8. |
| [50] | Ibrahim HS, Froemming GR, Omar E, Singh HJ: ACE2 activation by xanthenone prevents leptin-induced increases in blood pressure and proteinuria during pregnancy in Sprague-Dawley rats. Reprod Toxicol 2014, 49: 155-161. |
| [51] | Bellmeyer A, Martino JM, Chandel NS, Scott Budinger GR, Dean DA, Mutlu GM: Leptin resistance protects mice from hyperoxia-induced acute lung injury. Am J Respir Crit Care Med 2007, 175: 587-594. |
| [52] | Pigoga JL, Friedman A, Broccoli M, Hirner S, Naidoo AV, Singh S, Werner K, Wallis LA: Clinical and historical features associated with severe COVID-19 infection: a systematic review. medRxiv 2020: 2020.2004.2023.20076653. |
| [53] | Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, et al: Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020, 323: 1574-1581. |
| [54] | Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, Madhur MS, Tomaszewski M, Maffia P, D'Acquisto F, et al: COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020, 116: 1666-1687. |
| [55] | Alexander RW: Hypertension and the Pathogenesis of Atherosclerosis. 1995, 25: 155-161. |
| [56] | Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O: Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiology 2020, 5: 831-840. |
| [57] | Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado del Pozo C, Prosper F, et al: Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell 2020, 181: 905-913. e907. |
| [58] | Boukhris M, Hillani A, Moroni F, Annabi MS, Addad F, Ribeiro MH, Mansour S, Zhao X, Ybarra LF, Abbate A, et al: Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective. The Canadian journal of cardiology 2020, 36: 1068-1080. |
| [59] | Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD: Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine 2020, 382: 1653-1659. |
| [60] | Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji MY, Cooper LT, Jr., Chahal CAA: Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart rhythm 2020, 17: 1463-1471. |
| [61] | Soumya RS, Unni TG, Raghu KG: Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports. Cardiovascular Drugs and Therapy 2020. |
| [62] | Hunt BJ: Bleeding and Coagulopathies in Critical Care. New England Journal of Medicine 2014, 370: 847-859. |
| [63] | Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z: D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. Journal of Thrombosis and Haemostasis 2020, 18. |
| [64] | Wu Z, McGoogan JM: Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020, 323: 1239-1242. |
| [65] | Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla A, Abosalif K, Ahmed Z, Younas S: COVID-19 and comorbidities: Deleterious impact on infected patients. Journal of Infection and Public Health 2020. |
| [66] | Yang J-K, Lin S-S, Ji X-J, Guo L-M: Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta diabetologica 2010, 47: 193-199. |
| [67] | Diamond B: The renin-angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications. The Journal of experimental medicine 2020, 217: e20201000. |
| [68] | Kuga T, Mohri M, Egashira K, Hirakawa Y, Tagawa T, Shimokawa H, Takeshita A: Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol 1997, 30: 108-112. |
| [69] | Andreas D, Sebastian W, Peter D: Pharmacology and Cardiovascular Implications of the Kinin-Kallikrein System. Japanese Journal of Pharmacology 1999, 79: 403-426. |
| [70] | Crowley SD, Rudemiller NP: Immunologic Effects of the Renin-Angiotensin System. Journal of the American Society of Nephrology 2017, 28: 1350. |
| [71] | Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, Mast AE, Justice A, Aronow B, Jacobson D: A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. eLife 2020, 9: e59177. |
| [72] | Lee JY, Spicer AP: Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol 2000, 12: 581-586. |
| [73] | Harada H, Takahashi M: CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem 2007, 282: 5597-5607. |
| [74] | Hirano T, Murakami M: COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity 2020, 52: 731-733. |
| [75] | Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, Carbone GM, Cavalli A, Pagano F, Ragazzi E, et al: Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N=4532). Annals of oncology: official journal of the European Society for Medical Oncology 2020, 31: 1040-1045. |
| [76] | Mikkonen L, Pihlajamaa P, Sahu B, Zhang FP, Jänne OA: Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol 2010, 317: 14-24. |
| [77] | O'Callaghan ME, Jay A, Kichenadasse G, Moretti KL: Androgen deprivation therapy in unlikely to be effective for treatment of COVID-19. Annals of oncology: official journal of the European Society for Medical Oncology 2020, 31: 1780-1782. |
| [78] | Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020, 395: 1054-1062. |
| [79] | Khamitov RA, Loginova S, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM: [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. Voprosy virusologii 2008, 53: 9-13. |
| [80] | Thuy BTP, My TTA, Hai NTT, Hieu LT, Hoa TT, Loan HTP, Triet NT, Anh TTV, Quy PT, Tat PV, et al: Correction to Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil. In ACS omega, vol. 5. pp. 16315; 2020: 16315. |
| [81] | Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, et al: Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta pharmaceutica Sinica B 2020, 10: 766-788. |
| [82] | Huang J, Cao Y, Du J, Bu X, Ma R, Wu C: Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. Vaccine 2007, 25: 6981-6991. |
| [83] | Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, et al: Interim Results of a Phase 1–2a Trial of Ad26. COV2. S Covid-19 Vaccine. 2021. |
| [84] | Oz M, Lorke DE: Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. Biomedicine & Pharmacotherapy 2021, 136: 111193. |
| [85] | COVID19 Vaccine Tracker [https://covid19.trackvaccines.org/vaccines/5/]. |
| [86] | Nilsen TW: Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet 2007, 23: 243-249. |
| [87] | Nersisyan S, Shkurnikov M, Turchinovich A, Knyazev E, Tonevitsky A: Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2. PLOS ONE 2020, 15: e0235987. |
| [88] | Ragia G, Manolopoulos VG: Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. European journal of clinical pharmacology 2020, 76: 1623-1630. |
| [89] | Gupta I, Rizeq B, Elkord E, Vranic S, Al Moustafa AE: SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities. Cancers (Basel) 2020, 12. |
| [90] | Pinto BGG, Oliveira AER, Singh Y, Jimenez L, Goncalves ANA, Ogava RLT, Creighton R, Peron JPS, Nakaya HI: ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19. medRxiv 2020. |
| [91] | Yoichiro T, Akira H, Rie S, Haruki F, Megumi H, Rieko K, Takafumi O, Yoshihiko K: Research Square 2020. |
| [92] | Moderna: Moderna’s Work on a COVID-19 Vaccine Candidate. 16.11.2020 edition: ModernaTX, Inc./ Protocol Number mRNA-1273-P301; 2020. |
| [93] | Pfizer: PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY. 9.11.2020 edition; 2020. |
| [94] | Zhang K, Zhang Z, Kang J, Chen J, Liu J, Gao N, Fan L, Zheng P, Wang Y, Sun J: CRISPR/Cas13d-Mediated Microbial RNA Knockdown. 2020, 8. |
| [95] | Carbone M, Lednicky J, Xiao S-Y, Venditti M, Bucci E: Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2021: S1556-0864 (1520) 31140-31140. |
| [96] | Nguyen TM, Zhang Y, Pandolfi PP: Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses. Cell Research 2020, 30: 189-190. |
APA Style
Khandaker Atkia Fariha, Hasan Mahmud Syfuddin, Shamim Ahmed. (2021). An Insight into ACE2 Expression Associated Complexities of COVID-19 and the Possible Vaccine Strategies to Control Viral Entry into Host Cells. American Journal of Internal Medicine, 9(2), 58-69. https://doi.org/10.11648/j.ajim.20210902.11
ACS Style
Khandaker Atkia Fariha; Hasan Mahmud Syfuddin; Shamim Ahmed. An Insight into ACE2 Expression Associated Complexities of COVID-19 and the Possible Vaccine Strategies to Control Viral Entry into Host Cells. Am. J. Intern. Med. 2021, 9(2), 58-69. doi: 10.11648/j.ajim.20210902.11
AMA Style
Khandaker Atkia Fariha, Hasan Mahmud Syfuddin, Shamim Ahmed. An Insight into ACE2 Expression Associated Complexities of COVID-19 and the Possible Vaccine Strategies to Control Viral Entry into Host Cells. Am J Intern Med. 2021;9(2):58-69. doi: 10.11648/j.ajim.20210902.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajim.20210902.11,
author = {Khandaker Atkia Fariha and Hasan Mahmud Syfuddin and Shamim Ahmed},
title = {An Insight into ACE2 Expression Associated Complexities of COVID-19 and the Possible Vaccine Strategies to Control Viral Entry into Host Cells},
journal = {American Journal of Internal Medicine},
volume = {9},
number = {2},
pages = {58-69},
doi = {10.11648/j.ajim.20210902.11},
url = {https://doi.org/10.11648/j.ajim.20210902.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20210902.11},
abstract = {The first detected COVID-19 virus in China in late December 2019, has now spread to over 200 countries and territories across the globe. As it is a novel virus, in course of time, new symptoms and new complexities in patients have arisen, which demand immediate attention. This ambiguous, fast mutating nature and strain variations of SARS CoV2 have hindered the way of vaccine development. However, recognizing this new virus as a member of coronavidae family and its similarity with previously prevailed SARS-Cov virus has advantages in order for its further characterization and identification of the route of entry. Hence, this review aims at providing an overview of the viral entry pathway and explaining the reasons behind the vulnerability of an individual based on his/her age, sex, weight, other existing diseases and genetic make-up. It will also try to explicate various newly emerged symptoms of COVID-19 from the perspective of cytokinin storm theory. Furthermore, it summarizes all the therapeutic strategies based on preventing virus entry, some of which are already developed or under trial or yet confined in theory using currently published literature, scientific reports and research articles about SARS-CoV2. This review will help better understand the COVID-19 complicacies with latest concepts on therapeutic strategies against SARS-CoV2.},
year = {2021}
}
TY - JOUR T1 - An Insight into ACE2 Expression Associated Complexities of COVID-19 and the Possible Vaccine Strategies to Control Viral Entry into Host Cells AU - Khandaker Atkia Fariha AU - Hasan Mahmud Syfuddin AU - Shamim Ahmed Y1 - 2021/03/04 PY - 2021 N1 - https://doi.org/10.11648/j.ajim.20210902.11 DO - 10.11648/j.ajim.20210902.11 T2 - American Journal of Internal Medicine JF - American Journal of Internal Medicine JO - American Journal of Internal Medicine SP - 58 EP - 69 PB - Science Publishing Group SN - 2330-4324 UR - https://doi.org/10.11648/j.ajim.20210902.11 AB - The first detected COVID-19 virus in China in late December 2019, has now spread to over 200 countries and territories across the globe. As it is a novel virus, in course of time, new symptoms and new complexities in patients have arisen, which demand immediate attention. This ambiguous, fast mutating nature and strain variations of SARS CoV2 have hindered the way of vaccine development. However, recognizing this new virus as a member of coronavidae family and its similarity with previously prevailed SARS-Cov virus has advantages in order for its further characterization and identification of the route of entry. Hence, this review aims at providing an overview of the viral entry pathway and explaining the reasons behind the vulnerability of an individual based on his/her age, sex, weight, other existing diseases and genetic make-up. It will also try to explicate various newly emerged symptoms of COVID-19 from the perspective of cytokinin storm theory. Furthermore, it summarizes all the therapeutic strategies based on preventing virus entry, some of which are already developed or under trial or yet confined in theory using currently published literature, scientific reports and research articles about SARS-CoV2. This review will help better understand the COVID-19 complicacies with latest concepts on therapeutic strategies against SARS-CoV2. VL - 9 IS - 2 ER -
Email: